Immunotherapy is a rapidly evolving field. This guideline provides clinicians with trusted and up-to-date information with expert guidance on the nuances of the approved immunotherapy regimens.
MILWAUKEE (PRWEB)
June 15, 2023
The Society for Immunotherapy of Cancer (SITC), the world’s leading member-driven organization dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy, has published the first clinical practice guideline (CPG) focused on immunotherapy for the treatment of gynecologic cancer.
The new manuscript, “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancers”, was published in the Journal of ImmunoTherapy of Cancer (JITC), SITC’s peer-reviewed online journal, and it will be available in SITC’s mobile guidelines app.
“Immune checkpoint inhibitors have demonstrated strong activity in cervical and endometrial cancer,” said Mary (Nora) L. Disis, MD, FACP, co-Chair of the SITC Gynecologic Cancer Clinical Practice Guideline Expert Panel. “This has significantly changed how we treat these cancers and is offering extended survival for many patients compared to previous treatment options.”
While the integration of ICIs has undeniably improved patient outcomes, their usage in clinical practice necessitates careful consideration. Specific indications require PD-L1 expression or mismatch repair (MMR) status assessment, highlighting the critical importance of appropriate biomarker testing for each disease state. To address these complexities, the SITC Gynecologic Cancer Clinical Practice Guideline Expert Panel was assembled to develop evidence- and consensus-based recommendations, aiding clinicians in navigating the treatment landscape, biomarker testing, and other essential aspects such as considerations for special patient populations, quality of life concerns, and immunotherapy education for patients and caregivers.
“Immunotherapy is a rapidly evolving field. This guideline provides clinicians with trusted and up-to-date information with expert guidance on the nuances of the approved immunotherapy regimens,” said Kunle Odunsi, MD, PhD, co-Chair of the SITC Gynecologic Cancer Clinical Practice Guideline Expert Panel.
The manuscript, the latest installment in the ongoing series of SITC Cancer Immunotherapy Guidelines, is now available in the Journal for ImmunoTherapy of Cancer (JITC), SITC’s esteemed open access, peer-reviewed online journal. Furthermore, it will soon be accessible through SITC’s CPG Mobile App, ensuring widespread availability and accessibility.
“SITC’s clinical practice guidelines are a trusted and essential resource for clinicians seeking guidance on immunotherapy, developed by some of the most renowned experts in the field,” said SITC President Leisha Emens, MD, PhD. “Through the open-access publication in JITC, SITC’s free CPG Mobile App, and companion educational opportunities, SITC is committed to clinician education and improving patient care.”
In addition to the guideline, there are upcoming free live webinars offered by SITC and on-demand modules hosted on the SITC website focusing on topics within this guideline and providing attendees the opportunity to ask questions of expert faculty. View the page here to stay up-to-date with future webinar details.
About SITC
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn and YouTube.
About SITC’s Clinical Practice Guidelines
The SITC Cancer Immunotherapy Guidelines Program is a collection of clinical practice guidelines (CPGs) developed by multidisciplinary panels of experts who draw from practical experience as well as evidence in the published literature and clinical trial data to provide recommendations for clinicians on how and when to use immunotherapy to help improve outcomes for patients with cancer. SITC’s guidelines provide recommendations on topics including selection of appropriate immunotherapy treatments, toxicity management, biomarkers, and considerations for patient quality of life. SITC’s expanding catalogue of CPGs spans disease-state specific guidelines for several solid tumors, hematologic malignancies, and toxicity-specific guidelines to assist clinicians with the management of immune-related adverse events. You may access the entire series of CPGs in the Journal for ImmunoTherapy of Cancer (JITC), the society’s open access, peer-reviewed online journal, or in the CPG Mobile App.
About JITC
Journal for ImmunoTherapy of Cancer (JITC) is the official open access, peer-reviewed online journal of the Society for Immunotherapy of Cancer featuring an impact factor of 12.485. The journal publishes high-quality articles on all aspects of tumor immunology and cancer immunotherapy, on subjects across the basic science-translational-clinical spectrum. JITC publishes original research articles, literature reviews, position papers and practice guidelines, and case reports; invited commentaries may also be commissioned by the journal editors. These articles, freely accessible at jitc.bmj.com, make JITC the leading forum for tumor immunology and cancer immunotherapy research. Follow JITC on Twitter @jitcancer.
Share article on social media or email: